Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Net Margin for 6 consecutive years, with 22.8% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 496712280.0% to 22.8% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 164.43% through Dec 2025, up 43461395.0% year-over-year, with the annual reading at 164.43% for FY2025, 43461395.0% up from the prior year.
  • Net Margin for Q4 2025 was 22.8% at 4D Molecular Therapeutics, up from 63195.56% in the prior quarter.
  • The five-year high for Net Margin was 169910.53% in Q4 2023, with the low at 4967100.0% in Q4 2024.
  • Average Net Margin over 5 years is 396114.02%, with a median of 11008.23% recorded in 2023.
  • The sharpest move saw Net Margin crashed -513701053bps in 2024, then surged 496712280bps in 2025.
  • Over 5 years, Net Margin stood at 27264.13% in 2021, then surged by 92bps to 2195.59% in 2022, then soared by 7839bps to 169910.53% in 2023, then tumbled by -3023bps to 4967100.0% in 2024, then soared by 100bps to 22.8% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 22.8%, 63195.56%, and 364386.67% for Q4 2025, Q3 2025, and Q2 2025 respectively.